Shrimp protected from a virus by feed containing yeast with a surface-displayed viral binding protein

Ananphongmanee, Vorawit; Lertpreedakorn, Napathip; Taengchaiyaphum, Suparat; Charoenrat, Theppanya; Sritunyalucksana, Kallaya; Boonchird, Chuenchit

doi:10.1016/j.jbiotec.2021.09.014

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We will focus here on the budding yeast, Saccharomyces cerevisiae , which is the most popular yeast being developed into oral vaccines at this time ( Table 1 ). Two cousins of this budding yeast, Pichia pastoris and Kluyveromyces lactis , are also being tested as oral vaccines in a handful of animal models ( Seo et al, 2013 ; Zhao et al, 2014 ; Wang et al, 2016 ; Embregts et al, 2019 ; Ananphongmanee et al, 2021 ), but much less is known about the interactions of these yeasts with the mammalian digestive and immune systems.…”

Section: The Inherent Advantages Of Yeast Oral Vaccinesmentioning

confidence: 99%

“…However, many of them were also able to protect vaccinated animals against direct challenge from their target pathogen. These include candidate yeast oral vaccines against red-spotted grouper nervous necrosis virus in convict groupers ( Cho et al, 2017 ); Helicobacter pylori in mice ( Cen et al, 2021 ); cyprinid herpesvirus-3 in the common carp ( Ma et al, 2020 ); avian H5N1 influenza virus in chickens ( Lei et al, 2021b ); and white spot syndrome virus in shrimp ( Ananphongmanee et al, 2021 ), and among others. This growing list of successful animal vaccines suggests that cell-surface display is an effective technology for creating effective yeast oral vaccines.…”

Section: Emerging Yeast Oral Vaccines For Infectious Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Yeast oral vaccines against infectious diseases

Austriaco

2023

Front. Microbiol.

View full text Add to dashboard Cite

Vaccines that are delivered orally have several advantages over their counterparts that are administered via injection. Despite the advantages of oral delivery, however, approved oral vaccines are currently limited either to diseases that affect the gastrointestinal tract or to pathogens that have a crucial life cycle stage in the gut. Moreover, all of the approved oral vaccines for these diseases involve live-attenuated or inactivated pathogens. This mini-review summarizes the potential and challenges of yeast oral vaccine delivery systems for animal and human infectious diseases. These delivery systems utilize whole yeast recombinant cells that are consumed orally to transport candidate antigens to the immune system of the gut. This review begins with a discussion of the challenges associated with oral administration of vaccines and the distinct benefits offered by whole yeast delivery systems over other delivery systems. It then surveys the emerging yeast oral vaccines that have been developed over the past decade to combat animal and human diseases. In recent years, several candidate vaccines have emerged that can elicit the necessary immune response to provide significant protection against challenge by pathogen. They serve as proof of principle to show that yeast oral vaccines hold much promise.

show abstract

Section: The Inherent Advantages Of Yeast Oral Vaccinesmentioning

confidence: 99%

Section: Emerging Yeast Oral Vaccines For Infectious Diseasesmentioning

confidence: 99%

Yeast oral vaccines against infectious diseases

Austriaco

2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

VP28 interacts with PmRab7 irrespective of its nucleotide state

Sudsat,

Srisala,

Pakotiprapha

et al. 2024

Sci Rep

View full text Add to dashboard Cite

In shrimp aquaculture, white spot syndrome virus (WSSV) infections severely impact production. Previous research highlighted the crucial role of the Penaeus monodon Rab7 (PmRab7) protein in WSSV entry, specifically its interaction with the viral envelope protein VP28. PmRab7 exists in two conformations: GDP-bound (inactive) and GTP-bound (active). This study, using ELISA and isothermal titration calorimetry (ITC), reveals that the PmRab7-VP28 interaction occurs irrespective of the nucleotide binding state of PmRab7. Comparing the binding affinity between VP28 and different PmRab7 conformations, including wild-type (WT, 22.5 nM), a fast nucleotide exchange (L129F, 128 nM), a GDP-bound form (T22N, 334 nM), and a favorably GTP-bound form (Q67L, 1990 nM), PmRab7-WT exhibits the strongest binding affinity, especially at a lower temperature (25 °C). The binding of PmRab7-WT and VP28 in the presence of excess nucleotide (WT with excess GDP, 924 nM, and WT with excess GTP, 826 nM) shows a 2-fold higher binding affinity than in the absence (WT, 1920 nM) indicating that the addition of excess nucleotide for PmRab7-WT enhanced the affinity for VP28. Together, these findings support the potential of PmRab7-WT as a promising therapeutic candidate for WSSV control in shrimp. Furthermore, from an industrial point of view, the ITC platform developed to study the VP28-PmRab7 interactions provides a high-throughput method for screening additives for shrimp feed that can inhibit this interaction. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-024-79310-5.

show abstract

Shrimp protected from a virus by feed containing yeast with a surface-displayed viral binding protein

Cited by 2 publications

References 33 publications

Yeast oral vaccines against infectious diseases

Yeast oral vaccines against infectious diseases

VP28 interacts with PmRab7 irrespective of its nucleotide state

Contact Info

Product

Resources

About